-
Je něco špatně v tomto záznamu ?
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study
S. Kayser, RK. Hills, R. Langova, M. Kramer, F. Guijarro, Z. Sustkova, EH. Estey, CM. Shaw, Z. Ráčil, J. Mayer, P. Zak, MR. Baer, AM. Brunner, T. Szotkowski, P. Cetkovsky, D. Grimwade, RB. Walter, AK. Burnett, AD. Ho, G. Ehninger, C....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
Olympia-Morata fellowship program from the Medical Faculty of the Heidelberg University
15-25809A
Ministry of the Czech Republic
P50 CA100632
NCI NIH HHS - United States
PubMed
33529373
DOI
10.1111/bjh.17336
Knihovny.cz E-zdroje
- MeSH
- abnormální karyotyp MeSH
- akutní myeloidní leukemie epidemiologie genetika terapie MeSH
- analýza přežití MeSH
- dospělí MeSH
- fúzní onkogenní proteiny genetika MeSH
- indukce remise MeSH
- kombinovaná terapie MeSH
- konsolidační chemoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 16 ultrastruktura MeSH
- lidské chromozomy, pár 8 ultrastruktura MeSH
- mezinárodní spolupráce MeSH
- mladiství MeSH
- mutace MeSH
- myelodysplastické syndromy epidemiologie MeSH
- následné studie MeSH
- přežití bez známek nemoci MeSH
- progrese nemoci MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- sekundární malignity chemicky indukované epidemiologie MeSH
- sekvenování celého genomu MeSH
- senioři MeSH
- translokace genetická * MeSH
- transplantace hematopoetických kmenových buněk MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5·48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0·01) and those with complex karyotype (P = 0·04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0·04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.
Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA
Department of Epidemiology University of Washington Seattle WA USA
Department of Haematology Nottingham University Hospitals NHS Trust Nottingham UK
Department of Haematology School of Medicine Cardiff University Cardiff UK
Department of Internal Medicine 5 Heidelberg University Hospital Heidelberg Germany
Department of Medicine 1 University Hospital Carl Gustav Carus Dresden Germany
Department of Medicine University of Maryland School of Medicine Baltimore MD USA
Division Applied Bioinformatics German Cancer Research Center Heidelberg Germany
Division of Hematology Department of Medicine University of Washington Seattle WA USA
Faculty of Bioscience University of Heidelberg Heidelberg Germany
German Cancer Consortium Core Center Heidelberg Heidelberg Germany
IDIBAPS Hospital Clinic Barcelona Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
Massachusetts General Hospital Boston MA USA
NCT Trial Center National Center of Tumor Diseases German Cancer Research Center Heidelberg Germany
Nuffield Department of Population Health Oxford UK
Omics IT and Data Management German Cancer Research Center Heidelberg Germany
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore MD USA
University of Maryland Greenebaum Comprehensive Cancer Center Baltimore MD USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025996
- 003
- CZ-PrNML
- 005
- 20220627104043.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.17336 $2 doi
- 035 __
- $a (PubMed)33529373
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kayser, Sabine $u Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany $u NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- 245 10
- $a Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study / $c S. Kayser, RK. Hills, R. Langova, M. Kramer, F. Guijarro, Z. Sustkova, EH. Estey, CM. Shaw, Z. Ráčil, J. Mayer, P. Zak, MR. Baer, AM. Brunner, T. Szotkowski, P. Cetkovsky, D. Grimwade, RB. Walter, AK. Burnett, AD. Ho, G. Ehninger, C. Müller-Tidow, U. Platzbecker, C. Thiede, C. Röllig, A. Schulz, G. Warsow, B. Brors, J. Esteve, NH. Russell, RF. Schlenk, MJ. Levis
- 520 9_
- $a In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5·48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0·01) and those with complex karyotype (P = 0·04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0·04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.
- 650 _2
- $a abnormální karyotyp $7 D059786
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a lidské chromozomy, pár 16 $x ultrastruktura $7 D002885
- 650 _2
- $a lidské chromozomy, pár 8 $x ultrastruktura $7 D002898
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a konsolidační chemoterapie $7 D060830
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezinárodní spolupráce $7 D007391
- 650 _2
- $a akutní myeloidní leukemie $x epidemiologie $x genetika $x terapie $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a myelodysplastické syndromy $x epidemiologie $7 D009190
- 650 _2
- $a sekundární malignity $x chemicky indukované $x epidemiologie $7 D016609
- 650 _2
- $a fúzní onkogenní proteiny $x genetika $7 D015514
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a analýza přežití $7 D016019
- 650 12
- $a translokace genetická $7 D014178
- 650 _2
- $a sekvenování celého genomu $7 D000073336
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hills, Robert K $u Nuffield Department of Population Health, Oxford, UK
- 700 1_
- $a Langova, Ralitsa $u Division Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Faculty of Bioscience, University of Heidelberg, Heidelberg, Germany
- 700 1_
- $a Kramer, Michael $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
- 700 1_
- $a Guijarro, Francesca $u IDIBAPS, Hospital Clinic, Barcelona, Spain
- 700 1_
- $a Sustkova, Zuzana $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Estey, Elihu H $u Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA $u Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA
- 700 1_
- $a Shaw, Carole M $u Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA $u Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA
- 700 1_
- $a Ráčil, Zdeněk $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Zak, Pavel $u 4th Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Baer, Maria R $u University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA $u Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
- 700 1_
- $a Brunner, Andrew M $u Massachusetts General Hospital, Boston, MA, USA
- 700 1_
- $a Szotkowski, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Cetkovsky, Petr $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Grimwade, David $u Department of Medical & Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, UK
- 700 1_
- $a Walter, Roland B $u Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA $u Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA $u Department of Epidemiology, University of Washington, Seattle, WA, USA
- 700 1_
- $a Burnett, Alan K $u Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
- 700 1_
- $a Ho, Anthony D $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Ehninger, Gerhard, $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany $d 1952- $7 xx0274365
- 700 1_
- $a Müller-Tidow, Carsten $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Platzbecker, Uwe $u Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
- 700 1_
- $a Thiede, Christian $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
- 700 1_
- $a Röllig, Christoph $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
- 700 1_
- $a Schulz, Angela $u Genomics and Proteomics Core Facility High Throughput Sequencing, German Cancer Research Center (DKFZ), Heidelberg, Germany
- 700 1_
- $a Warsow, Gregor $u Omics IT and Data Management, German Cancer Research Center (DKFZ), Heidelberg, Germany
- 700 1_
- $a Brors, Benedikt $u Division Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany $u German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany
- 700 1_
- $a Esteve, Jordi $u IDIBAPS, Hospital Clinic, Barcelona, Spain
- 700 1_
- $a Russell, Nigel H $u Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
- 700 1_
- $a Schlenk, Richard F $u NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany $u Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Levis, Mark J $u Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 192, č. 5 (2021), s. 832-842
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33529373 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20220627104041 $b ABA008
- 999 __
- $a ok $b bmc $g 1714874 $s 1146503
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 192 $c 5 $d 832-842 $e 20210202 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- GRA __
- $p Olympia-Morata fellowship program from the Medical Faculty of the Heidelberg University
- GRA __
- $a 15-25809A $p Ministry of the Czech Republic
- GRA __
- $a P50 CA100632 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20211013
